A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
New research shows the nervous system contributes to pancreatic cancer development before tumors fully form, with nerve fibers and support cells creating a self-sustaining loop that promotes cancer growth. Blocking nerve activity reduced tumor growth by nearly 50% in experiments.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05675059 |
Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients |
ACTIVE_NOT_RECRUITING | NA |
| NCT04662879 |
Early Detection Initiative for Pancreatic Cancer |
ACTIVE_NOT_RECRUITING | NA |
| NCT04581343 |
A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients |
COMPLETED | PHASE1 |
| NCT04229004 |
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer |
COMPLETED | PHASE3 |
| NCT03848182 |
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer |
TERMINATED | PHASE2 |
| NCT03192462 |
TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer |
COMPLETED | PHASE1/PHASE2 |
